Estrogen positive breast cancers are currently treated with three types of agents: selective estrogen receptor modulators (tamoxifen), estrogen synthesis inhibitors (aromatase inhibitors) and selective estrogen receptor down-regulators (fulvestrant) [167]. This evidence concerns the gene CYP19A1 and breast cancer.